

Strong Homology Between Colonizing and Bloodstream Carbapenem-Resistant *Acinetobacter* Spp.: Implications for Empiric Antibiotic Therapy in Hematological Patients

Jia Li^{1,2}, Wenjing Guo^{1,2}, Jieru Wang^{1,2}, Xiaomeng Feng^{1,2}, Qingsong Lin^{1,2,*}, Yizhou Zheng^{1,2}, Fengkui Zhang^{1,2}, Yingchang Mi^{1,2}, Xiaofan Zhu^{1,2}, Erlic Jiang^{1,2}, Zhijian Xiao^{1,2}, Jianxiang Wang^{1,2}, Sizhou Feng^{1,2,*}

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, People's Republic of China; ²Tianjin Institutes of Health Science, Tianjin, 301600, People's Republic of China

*These authors contributed equally to this work

Correspondence: Sizhou Feng, Hematopoietic Stem Cell Transplantation Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 288 Nanjing Road, Tianjin, 300020, People's Republic of China, Tel +86-022-23909162, Fax +022-23909047, Email doctor_szhfeng@163.com; szfeng@ihcams.ac.cn

Objective: This study aimed to assess the impact of colonization status on the outcomes of *Acinetobacter* spp. bloodstream infection (BSI) and investigate the homology and within-host evolution between colonizing and bloodstream carbapenem-resistant *Acinetobacter* spp. (CRA) to inform antibiotic therapeutic decisions.

Methods: We analyzed clinical outcomes of 46 hematological patients with *Acinetobacter* spp. BSI and performed whole-genome sequencing on the remaining CRA isolates.

Results: Among the patients, 39.1% (n=18) had prior *Acinetobacter* spp. colonization. Colonized patients had higher rates of polymicrobial BSI (50.0% vs 21.4%, P=0.044) and CRA BSI (72.2% vs 17.9%, P<0.001), resulting in elevated inflammatory markers and increased 30-day mortality. Each of the eight pairs of the remaining respiratory colonizing and bloodstream CRA strains belonged to the same genomospecies. Each pair exhibited definitive agreement in at least 21 of the 22 most representative antibiotic susceptibility tests. The minimum spanning tree based on multilocus sequence typing (MLST) and phylogenetic trees based on MLST and single nucleotide polymorphism (SNP) all indicated that each pair shared the same minimum branch. Very few non-synonymous SNPs in genic regions were identified during the transition from respiratory colonization to bloodstream infection, with minimal changes in virulence genes. Homology analysis suggested that CRA BSI originated from colonizing isolates in the respiratory tract.

Conclusion: Strict infection control measures are needed to manage *Acinetobacter* spp. colonisation in hematological patients. Appropriate empirical therapy can be administered for suspected CRA BSI based on the antimicrobial minimum inhibitory concentration of CRA colonising the respiratory tract.

Keywords: *Acinetobacter*, colonization, bloodstream infections, homology, therapy, carbapenem-resistant

Introduction

Acinetobacter spp. is a complex genus that has become a common pathogen of nosocomial infections.^{1,2} *Acinetobacter baumannii* (*A. baumannii*) is one of the most significant pathogens causing bloodstream infections (BSIs) associated with *Acinetobacter* spp. The mortality rate of *Acinetobacter* spp. BSI has been reported to be between 33–68% within 30 days of diagnosis.^{3–6} Appropriate treatment decisions and effective preventive measures are necessary to reduce the high mortality rate.

Research has shown that inappropriate empirical antibiotic treatment can lead to adverse outcomes in patients with nosocomial Gram-negative bacilli (GNB), particularly in cases of *Acinetobacter* spp. infections.^{3,7–10} Our unpublished data suggested that hematological patients with inappropriate empirical therapy had a mortality rate of up to 66.7%. However, one study indicated that 88% of patients with *Acinetobacter* spp. BSI initially received inappropriate antibiotic therapy.⁷ Additionally, colonisation has been proven to be an independent risk factor for bacteremia.^{11–14} Although several studies have analyzed the risk factors for developing bacteremia in colonised patients,^{11,15} none has reported the impact of colonisation on the clinical outcomes of subsequent bacteremia. Previous studies^{13,16} have compared the homology of colonising and bloodstream isolates, such as *Staphylococcus aureus* (*S. aureus*) and *Enterobacteriaceae*, but few studies have investigated *Acinetobacter* spp. colonisation. At present, respiratory colonisation provides limited information for clinicians when making appropriate treatment decisions for *Acinetobacter* spp. BSI.

This study compared clinical outcomes in haematological patients during *Acinetobacter* spp. BSI stratified by colonisation status. Moreover, we aimed to investigate the homology and within-host evolution between respiratory colonising and bloodstream carbapenem-resistant *Acinetobacter* spp. (CRA) strains to provide a molecular basis for appropriate empirical antibiotic treatment of bacteremia.

Patients and Methods

Study Design

We included all patients diagnosed with haematological diseases and *Acinetobacter* spp. BSI between April 2013 and June 2023 at a 766-bed tertiary blood disease hospital in Tianjin, China. We analyzed their clinical outcomes stratified by colonization status. In addition, we compared the homology between colonizing and bloodstream CRA strains to guide appropriate empirical antibiotic treatment.

To achieve this, we first used genome sequencing to identify the genomospecies of the available 21 CRA isolates, which included 8 pairs of respiratory and bloodstream strains from the same infection period. We then compared the antibiotic susceptibility profiles between each pair of CRA strains. Finally, we performed multilocus sequence typing (MLST) and single nucleotide polymorphism (SNP) analyses on each pair of CRA strains to determine genetic relationships and within-host evolution. The Ethics Committee of the Institute of Hematology and Blood Diseases Hospital approved this study. All patients or guardians provided informed written consent per the Declaration of Helsinki.

Definitions

The onset of BSI was defined as the collection date of positive blood culture samples, and laboratory examinations such as procalcitonin (PCT) and C-reactive protein (CRP) were performed within 24 h.¹⁷ Patients underwent sputum cultures and were examined for bacterial colonization in the nasal cavity, pharynx, and perianal skin using cotton swabs dipped in 0.9% sterile saline. These procedures were conducted twice a week. Positive blood cultures were assessed as clinically significant or contaminants based on organism type, clinical signs, culture results, and clinical course.¹⁸ Bacteremias were considered as polymicrobial when two or more clinically significant microorganisms were isolated in the same set of blood cultures. The definitions for carbapenem-resistant (CR), multidrug-resistant (MDR), and extensively drug-resistant (XDR) *Acinetobacter* spp. were defined according to previously reported criteria.¹⁹ The definitions of sepsis or septic shock followed the 2021 Surviving Sepsis Campaign Guidelines.²⁰ The following cut-off values were used for the primary analysis: 0.5 µg/L for PCT and 10 mg/L for CRP. Previous antibiotic use was defined as the administration of any antibiotic for ≥48 h within the month before the onset of BSI. Empirical antibiotic therapy was defined as any antibiotic administered to febrile patients suspected of having bacteremia before susceptibility results were available. Appropriate empirical antibiotic therapy was defined as the administration of one or more active agents against *Acinetobacter* spp. at an adequate dose within 24 h after the culture was obtained. Definition of clinical cure: local infection disappeared, body temperature returned to normal, chest CT showed that the shadow of the lung disappeared, and blood indexes (PCT, CRP) returned to normal.

Antimicrobial Susceptibility Testing and Strain Preservation

Antibiotic susceptibility testing was conducted at the hospital's microbiology laboratory using an automated system, VITEK 2 Compact (Bio m rieux Inc., Hazcwood, Mo, USA). The interpretation of antibiotic susceptibilities followed the guidelines established by the Clinical and Laboratory Standards Institute M100 (YEAR 2023).²¹ The microbiology laboratory has retained CRA strains from 2017 to the present. This collection comprises 8 pairs of strains, each consisting of both respiratory and bloodstream isolates obtained during the same infection period, along with 5 individual bloodstream CRA strains. The strains were collected using filter paper in a strain storage tube and stored in a refrigerator at -80°C .

Bacterial Strain and DNA Extraction

Following the revival of the previously preserved CRA strains in the laboratory, a single colony was inoculated onto blood agar medium and incubated at 37°C with 5% CO_2 for 20 hours. Genomic DNA was extracted from cell pellets using a Bacteria DNA Kit (OMEGA) following the manufacturer's instructions. Purified DNA samples underwent quality control assessment, and high-quality DNA samples ($\text{OD}_{260/280}=1.8\sim 2.0$, $>6\mu\text{g}$) were used for fragment library construction.

Library Construction and Illumina HiSeq Sequencing

Sequencing was conducted by Shanghai Biozeron Biotechnology Co., Ltd. (Shanghai, China). For Illumina paired-end sequencing, a minimum of $1\mu\text{g}$ of genomic DNA was employed. Paired-end libraries with 400bp insert sizes were prepared following Illumina's standard protocol. Purified genomic DNA was fragmented, blunt ends generated, adapters ligated, and fragments purified, enriched, and PCR amplified. The qualified Illumina paired-end library was used for Illumina NovaSeq 6000 sequencing (150bp*2).

Genome Assembly

Raw paired-end reads were trimmed and quality controlled using Trimmomatic. Clean data from these quality control processes were used for further analysis. Genome assembly was performed using ABySS with multiple-Kmer parameters, and GapCloser software filled remaining gaps and corrected base polymorphisms. Whole Genome Sequencing (WGS) results facilitated the reclassification of CRA strains in accordance with Genome Taxonomy Database,²² and the project was deposited in GenBank under the accession number PRJNA883531.

MLST Analysis

The housekeeper gene sequences of *cpn60*, *fusA*, *gltA*, *pyrG*, *recA*, *rplB* and *rpoB* were analysed based on the latest pubmlst database, according to the Pasteur multilocus sequence typing (MLST) scheme, to obtain the allelic profiles and sequence types (STs). The phylogenetic tree based on MLST was constructed by RAxML-NGv.0.9.0, and the clusters and minimum spanning tree based on MLST were constructed by BioNumerics.

SNP Analysis

We aligned each sample to the reference sequence using MUMmer software and identified potential single nucleotide polymorphism (SNP) sites. To verify and filter the SNP sites, we compared the extracted sequence with the assembly results using BLAT software. We obtained reliable SNPs and constructed phylogenetic trees by the maximum likelihood method using PhyML software.²³ Coding proteins were functionally classified according to Clusters of Orthologous Groups of proteins (COG) database.

Statistical Analysis

Statistical Product and Service Solutions (SPSS) software (version 24.0; Chicago, IL, USA) was used to analyse the data. Categorical variables were compared using the chi-squared or Fisher's exact tests. Continuous variables were expressed as the median and interquartile range (IQR), and differences were identified using the two-sample *t*-test or Mann-Whitney *U*-test. The Kaplan-Meier method was used to plot survival curves (Log rank test). Statistical significance was set at P -values <0.05 .

Results

Clinical Outcomes Stratified by Colonization Status

This study retrospectively analysed 46 patients diagnosed with haematological diseases and *Acinetobacter* spp. BSI between 2013 and 2023. Of 46 patients, 50.0% were male, with a median age of 25.5 years (range: 1–62 years) (Table S1). The underlying diseases included very severe aplastic anaemia, acute lymphoblastic leukaemia, acute myeloid leukaemia, myelodysplastic syndrome, diffuse large B-cell lymphoma and β -thalassaemia. Table 1 summarizes the clinical outcomes of hematological patients with *Acinetobacter* spp. BSI based on their colonization status. Of the total patients, 39.1% (n=18) had prior *Acinetobacter* spp. colonisation, with one in the perianal area and the remaining in the respiratory tract. These colonized patients had significantly higher median levels of PCT (median, 1.46 [IQR, 0.71–8.32] vs median, 0.17 [IQR, 0.09–0.69]; P=0.008) and CRP (median, 92.29 [IQR, 16.50–194.00] vs median, 12.88 [IQR, 5.65–51.85]; P=0.013) during their *Acinetobacter* spp. BSI. Furthermore, they were at an increased risk of developing polymicrobial BSI (50.0% vs 21.4%, P=0.044). During their bacteremia, they also had higher rates of respiratory failure (38.9% vs 10.7%, P=0.033) and sepsis or septic shock (44.4% vs 10.7%, P=0.014).

The present study also found that *Acinetobacter* spp. colonization increased the risk of subsequent MDR *Acinetobacter* spp. (MDRA) BSI (77.8% vs 25.0%, P<0.001). Among patients with colonization, the bloodstream isolates had significantly higher rates of drug resistance to carbapenems, fluoroquinolones, aminoglycosides and piperacillin-tazobactam (72.2%, 50.0%, 50.0% and 77.8%, respectively) than those without colonization. XDR *Acinetobacter* spp. (XDRA) BSI (22.2% vs 3.6%, P=0.069) was marginally common in the colonized patients. Additionally, colonized patients were more likely to receive inappropriate empirical antibiotic therapy within 24 hours (66.7% vs 14.3%, P<0.001). Notably, colonized patients had a significantly lower 30-day clinical cure rate (22.2% vs 64.3%, P=0.005) and higher 30-day mortality rate (50.0% vs 21.4%, P=0.044) after the onset of bacteremia. The survival analysis revealed a significant difference in the 30-day survival

Table 1 Comparison of Outcomes in Hematological Patients During *Acinetobacter* Spp. Bloodstream Infection, Stratified by *Acinetobacter* Spp. Colonization Status

Outcomes	Total n=46	Colonized n=18	Not Colonized n=28	P value
Resistance profiles of BSI				
Carbapenem-resistant	18 (39.1)	13 (72.2)	5 (17.9)	<0.001*
Multidrug-resistant	21 (45.7)	14 (77.8)	7 (25.0)	<0.001*
Extensively drug-resistant	5 (10.9)	4 (22.2)	1 (3.6)	0.069
Fluoroquinolones-resistant	13 (28.3)	9 (50.0 ^b)	4 (14.3)	0.009*
Aminoglycosides-resistant	14 (30.4)	9 (50.0)	5 (17.9)	0.021*
Piperacillin-tazobactam-resistant	19 (41.3)	14 (77.8)	5 (17.9)	<0.001*
Inappropriate empirical therapy	16 (34.8)	12 (66.7)	4 (14.3)	<0.001*
Polymicrobial BSI	15 (32.6)	9 (50.0)	6 (21.4)	0.044*
Laboratory results at the onset of BSI				
PCT (ug/L)	0.49 (0.12–1.89)	1.46 (0.71–8.32)	0.17 (0.09–0.69)	0.008*
CRP (mg/L)	31.81 (10.43–123.71)	92.29 (16.50–194.00)	12.88 (5.65–51.85)	0.013*
Respiratory failure	10 (21.7)	7 (38.9)	3 (10.7)	0.033*
Sepsis or septic shock	11 (23.9)	8 (44.4)	3 (10.7)	0.014*
30-day clinical recovery	22 (47.8)	4 (22.2)	18 (64.3)	0.005*
30-day death	15 (32.6)	9 (50.0)	6 (21.4)	0.044*

Note: Categorical variables are presented as numbers (percentiles); continuous variables are presented as median (interquartile range, IQR). A P value in italics and bold means <0.1, followed by * means <0.05.

Abbreviations: OR, odds ratio; CI, confidence interval; PCT, procalcitonin; CRP, C-reactive protein; AST, aspartate aminotransferase. BSI, bloodstream infection.

probability between patients with previous *Acinetobacter* spp. colonization and those with a negative colonization status (78.6% [95% CI: 67.4–98.7%] vs 50.0% [95% CI: 30.0–74.1%], $P=0.045$) (Figure 1).

Antibiotic Susceptibility Profiles and Genomospecies

The majority of CRA isolates in our study were identified as *A. baumannii* or the *A. calcoaceticus-baumannii* (Acb) complex using VITEK 2 Compact. We observed almost identical antibiotic susceptibility profiles for each of the eight pairs of respiratory-bloodstream CRA strains (Table S2). These profiles showed definitive agreement for at least 21 of the 22 most representative antibiotic susceptibility tests. Therefore, we resuscitated a total of 21 CRA strains that were accessible in the microbiology laboratory. This collection comprised 8 pairs of strains, each consisting of respiratory and bloodstream isolates obtained during the same infection period, as well as 5 individual bloodstream isolates. The genome sequencing revealed the identification of *A. pittii* (nine), *A. baumannii* (nine), *A. oleivorans* (two), and *A. nosocomialis* (one). We also determined that each of the eight pairs of respiratory and bloodstream CRA strains from the same infection period belonged to the same genomospecies (Table 2).

High Genetic Similarity Based on MLST and SNP

Table 2 displays the sequence types (STs) of the CRA strains, as determined by the Pasteur MLST scheme. In addition to the seven known STs, we identified five new housekeeping genes and four new STs that have not been reported internationally. To determine genetic similarity, we conducted phylogenetic analyses based on genome sequencing. The MLST phylogenetic tree demonstrated that each of the eight pairs of respiratory-bloodstream CRA strains shared the same minimum branch (Figure 2). The MLST minimum spanning tree (Figure 3) connected isolates within the same clonal complexes with solid black lines, indicating their closest kinship. The respiratory-bloodstream CRA strains of case 6 were grouped into a clonal complex, whereas each of the other seven pairs of respiratory-bloodstream CRA strains exhibited an identical MLST pattern.




Figure 1 Kaplan-Meier curves of the 30-day probability of survival in hematological patients with *Acinetobacter* spp. bloodstream infection, comparing patients with and without previous *Acinetobacter* spp. colonization.

Table 2 The Sequence Types of 21 Carbapenem-Resistant *Acinetobacter* Spp. Isolates and Four Reference Types Using the Pasteur Multilocus Sequence Typing (MLST) Scheme

Sample ID	Case ID	Strain	Housekeeping Genes							STs
			<i>cpn60</i>	<i>fusA</i>	<i>gltA</i>	<i>pyrG</i>	<i>recA</i>	<i>rplB</i>	<i>rpoB</i>	
A-6	Case 1	<i>A. pittii</i>	17	21	23	10	20	18	27	248
A-8	Case 1	<i>A. pittii</i>	17	21	23	10	20	18	27	248
A-32		<i>A. pittii</i>	17	21	23	10	488	13	20	2230
A-37		<i>A. pittii</i>	17	20	23	10	20	13	20	63
A-44	Case 2	<i>A. baumannii</i>	2	2	2	2	2	2	2	2
A-45	Case 2	<i>A. baumannii</i>	2	2	2	2	2	2	2	2
A-69		<i>A. baumannii</i>	3	1	16	1	7	2	3	1627
A-76	Case 3	<i>A. baumannii</i>	2	2	2	2	2	2	2	2
A-77	Case 3	<i>A. baumannii</i>	2	2	2	2	2	2	2	2
A-136	Case 4	<i>A. pittii</i>	17	21	23	10	20	18	27	248
A-140	Case 4	<i>A. pittii</i>	17	21	23	10	20	18	27	248
A-169	Case 5	<i>A. baumannii</i>	2	2	2	2	2	2	2	2
A-172	Case 5	<i>A. baumannii</i>	2	2	2	2	2	2	2	2
A-193		<i>A. nosocomialis</i>	47	47	50	14	26	16	49	224
A-223	Case 6	<i>A. pittii</i>	17	20	23	10	20	131	446	2229
A-225	Case 6	<i>A. pittii</i>	17	20	23	10	20	131	20	1611
A-231	Case 7	<i>A. baumannii</i>	1	2	2	2	5	1	2	105
A-233	Case 7	<i>A. baumannii</i>	1	2	2	2	5	1	2	105
A-337	Case 8	<i>A. oleivorans</i>	491	94	434	38	33	22	447	2231
A-339	Case 8	<i>A. oleivorans</i>	491	94	434	38	33	22	447	2231
A-340		<i>A. pittii</i>	17	20	23	10	20	131	20	1611
ATCC 19606		<i>A. baumannii</i>	3	2	2	7	9	1	5	52
NIPH 2119		<i>A. nosocomialis</i>	20	26	26	18	27	19	23	76
JCM 16667		<i>A. oleivorans</i>	78	94	71	38	82	22	72	560
DSM 25618		<i>A. pittii</i>	17	20	23	10	20	13	20	63

Note: Only case IDs of patients who had respiratory colonization were noted. The new housekeeping genes and STs are marked in bold. STs, sequence types.

Considering that ST-2 is a prevalent epidemic strain worldwide,^{24,25} we conducted a comparative genomics analysis based on the complete genome sequence of strain A-169 (*A. baumannii*, ST-2). A total of 348,540 SNPs were identified in all bloodstream CRA isolates by comparing them with the genome of strain A-169. Consistent with the MLST findings, each pair of respiratory-bloodstream CRA strains from the same patient was classified into one clade in the SNP-based phylogenetic tree, indicating their high degree of genetic similarity (Figure 4). Collectively, the homology analysis results above suggest that these respiratory strains were likely the direct origin of CRA BSI.




Figure 2 The phylogenetic tree of 21 carbapenem-resistant *Acinetobacter* spp. strains and 4 type strains inferred from a concatenate of the seven alleles used in the Pasteur multilocus sequence typing (MLST) scheme. RT, respiratory tract.




Figure 3 The minimum spanning tree of 21 carbapenem-resistant *Acinetobacter* spp. (CRA) strains and 4 type strains inferred from a concatenate of the seven alleles used in the Pasteur multilocus sequence typing (MLST) scheme. The sequence types (STs) are indicated by the numbers beside each circle, with the size of each circle proportional to the number of isolates belonging to the same ST type. Branch values indicate the number of loci that differ between adjacent nodes. Grey shading is used to represent the same cluster. Each of the eight pairs of respiratory-bloodstream CRA strains had an identical MLST pattern or was grouped into a clonal complex.




Figure 4 The phylogenetic tree of 21 carbapenem-resistant *Acinetobacter* spp. strains based on single nucleotide polymorphisms between each strain and strain A-169 by maximum likelihood method. RT, respiratory tract.

Limited Within-Host Evolution

To investigate the genomic evolution from respiratory tract carriage to bloodstream infection, we analyzed SNPs between colonising and bloodstream CRA strains from eight patients with CRA BSI. On average, each bloodstream isolate carried 21 SNPs in 3 to 7 genes, and synonymous SNPs occurred more frequently than non-synonymous SNPs in most patients with a ratio of 5.5:1 (Figure 5A). Functional analysis revealed that most mutations were enriched in genes associated with energy production and conversion, lipid transport and metabolism, and translation, ribosomal structure and biogenesis. (Figure 5B).

We identified all non-synonymous genic SNPs and determined the corresponding base and amino acid changes. Table 3 summarizes the names or functions and the function classes of the corresponding genes. We found a nonsense mutation on *rnd*, which encodes ribonuclease D, and a stop codon mutation on *pdaA*, which encodes polysaccharide deacetylase. SNPs were also found in *ahpF*, *TMP*, *pdaA* and *Ata* genes, which encode alkyl hydroperoxide reductase subunit F, phage tail tape measure protein, polysaccharide deacetylase, and autotransporter adhesin, respectively. Notably, a mutation in the housekeeper gene *rpo* was




Figure 5 (A) The genic and intergenic single nucleotide polymorphisms (SNPs) identified during within-host evolution. (B) Function class of genes with all SNPs based on the Clusters of Orthologous Groups of proteins (COG).

Table 3 Non-Synonymous Genic Single Nucleotide Polymorphisms (SNPs) Found from Respiratory Tract Carriage to Bloodstream Infection in Eight Patients with Carbapenem-Resistant *Acinetobacter* Spp.

Case ID	Reference Gene	Base change	Amino Acid Change	Mutation Type	Gene or Function	Function Class
Case 1	A-6001176 A-6003774 A-6003782	C—T T—C C—A	Gln—X Asn—Asp Pro—Gln	Nonsense Missense Missense	<i>rnd</i> <i>ahpF</i> Hypothetical protein J604-3711	J C NA
Case 2	A-45003484 A-45001662	T—A T—A	Glu—Asp Glu—Asp	Missense Missense	3-oxoadipate CoA-transferase subunit A 3-oxoadipate CoA-transferase subunit A	I I
Case 3	A-76003056 A-76003660 A-76003686	T—A T—G A—T	Tyr—Asn Lys—Gln Leu—Phe	Missense Missense Missense	Hypothetical protein <i>TMP</i> <i>ahpF</i>	NA D C
Case 4	A-140003692 A-140003805 A-140003815	C—T T—C C—G	Arg—Lys Ile—Val Ser—Thr	Missense Missense Missense	Integrase Hypothetical protein ABAYE1233 <i>ahpF</i>	L NA C
Case 5	A-172003570	A—G	Leu—Ser	Missense	<i>TMP</i>	NA
Case 6	A-225002091 A-225001841	C—T A—G	Ser—Leu Val—Ala	Missense Missense	<i>rpoB</i> (RNA polymerase subunit B) Histidine kinase	K T
Case 7	A-231000349 A-231003655 A-231003655 A-231003655 A-231003655 A-231001249	T—C T—C C—G A—T A—C T—G	X—Trp Ser—Pro Ser—Cys Leu—Phe Ile—Leu Lys—Asn	Stop codon mutation Missense Missense Missense Missense Missense	<i>pdaA</i> Transposase and inactivated derivatives Transposase and inactivated derivatives Transposase and inactivated derivatives Transposase and inactivated derivatives <i>Ata</i>	G L L L L UW
Case 8	A-339001866 A-339001875	G—A G—A	Arg—Cys Arg—Cys	Missense Missense	DUF932 domain-containing protein DUF932 domain-containing protein	NA NA

Notes: SNPs of the genomes were identified by mapping sequence reads for each bloodstream isolate against the corresponding respiratory isolate in each patient.

Abbreviations: X, unknown amino acid; nonsyn, non-synonymous; C—T, the base of the respiratory sample changed from C into T in bacteremia. Functional classification: NA, unknown function; C, energy production and conversion; D, cell cycle control, cell division, chromosome partitioning; G, carbohydrate transport and metabolism; I, lipid transport and metabolism; J, translation, ribosomal structure and biogenesis; K, transcription; L, replication, recombination and repair; T, signal transduction mechanisms; U, intracellular trafficking, secretion, and vesicular transport; W, extracellular structures.

detected in one patient (case 6) during the breakthrough into the bloodstream, resulting in a change in sequence type from ST1611 to ST2229. Only one non-synonymous SNP was detected in the virulence genes (*Ata* gene coding autotransporter adhesin).

Discussion

We observe that the prevalence of *Acinetobacter* spp. BSI among patients with hematologic disorders is low and has been infrequently documented. A multicenter study conducted from January 2014 to June 2015 in the hematology wards of 18 tertiary hospitals in China reported that *A. baumannii* bacteremia accounted for only 2.9% (40/1358) of all cases of bacteremia.²⁶ In our own study, we included a total of 46 patients with *Acinetobacter* spp. BSI over a 10-year follow-up period in a large hematology hospital. Nevertheless, it is essential to emphasize the high mortality rate associated with hematologic patients who have concurrent *Acinetobacter* spp. BSI, warranting careful consideration.

In the last few years, *A. pittii*, *A. calcoaceticus*, *A. lwoffii*, *A. junii*, *A. soli*, *A. ursingii*, *A. bereziniae* and *A. nosocomialis* have gradually emerged as common pathogens of nosocomial infection.^{1,2} *A. oleivorans*, traditionally recognized as an oil-degrading bacterium and a focus of environmental engineering studies, has recently been identified as a human pathogen as well.^{27,28} The propensity of *Acinetobacter* spp. to colonize and infect critically ill patients often leads to a poor prognosis.⁷ It has been widely reported that selective pressure from colonisation is an independent risk factor associated with breakthrough Gram-negative bacteremia,^{11–14,29} particularly during carbapenem therapy.¹² Empirical

antibiotic therapy is a critical component in the treatment of *Acinetobacter* spp. BSI.²⁶ In a large multicenter study, inappropriate empirical antibiotic therapy was found to nearly doubled hospital mortality in patients with *A. baumannii* pneumonia and sepsis (adjusted RRR 1.8, 95% CI 1.4–2.3, $P < 0.001$).⁸ Therefore, optimizing empirical antibiotic therapy for patients with *Acinetobacter* spp. BSI is a pressing concern, given the increasing resistance rates to existing antibiotics.

According to a study,³⁰ polymicrobial *A. baumannii* BSI accounted for 19.1% (39/204) of all *A. baumannii* BSI cases. Moreover, the resistance rate of *A. baumannii* to imipenem, cefepime, tobramycin, piperacillin/tazobactam, and ciprofloxacin was significantly higher in the polymicrobial *A. baumannii* BSI group than in the monomicrobial *A. baumannii* BSI group. While colonization pressure has been suggested as a promoter of acquiring MDR bacteria, it has not been widely studied for *Acinetobacter* spp.^{31,32} In the present study, we found that the colonized patients had an increased risk of developing polymicrobial BSI. Additionally, *Acinetobacter* spp. colonization significantly increased the resistance rates of *Acinetobacter* spp. BSI to multiple antibiotics. Consequently, the increased incidence of CRA and MDRA BSI in our study raised the possibility of patients receiving inappropriate empirical antibiotic therapy, leading to higher levels of inflammatory indicators and higher 30-day mortality. Based on our findings, colistin appears to be the most effective therapeutic option against the isolates identified in our study.

There have been limited investigations into the molecular correlation between colonizing and bloodstream *Acinetobacter* spp. Moreover, clinical bacterial identification methods often classify *Acinetobacter* spp. strains as Acb complex or *A. baumannii* due to their limitations.³³ Popular molecular epidemiology methods, such as MLST, pulsed-field gel electrophoresis (PFGE) and WGS, can be used to identify genetic similarity.³⁴ For instance, Johanna et al¹³ performed PFGE on nine hemodialysis patients colonized by *S. aureus* who later presented with bacteremia caused by the same bacteria. The Dice index revealed that 77.8% of patients were infected with the same strain previously identified as colonizing, with 100% similarity. Similarly, Michael et al¹⁶ confirmed that each of the ten pairs of colonizing and bloodstream isolates from patients with extended-spectrum β -lactamase (ESBL)-producing *Enterobacteriaceae* bacteremia had identical MLST patterns and ESBL genes. Additionally, PFGE indicated a genetic similarity of $>95\%$. In our study, we found that each of the eight pairs of colonizing and bloodstream CRA strains had identical genomospecies using gene sequence, with nearly identical antimicrobial susceptibility profiles for 22 tested antibiotics. Furthermore, in the MLST-based phylogenetic tree, MLST-based minimum spanning tree, and the SNP-based phylogenetic tree, each pair was divided into the same minimum branch, suggesting close genetic relatedness.

To gain a better understanding of the molecular mechanisms underlying within-host evolution of CRA BSI, we identified SNPs that accompanied the transition from respiratory tract colonization to bloodstream infection. In all cases, colonization progressed to bacteremia, with only one non-synonymous SNP detected in virulence genes. Specifically, the gene *Ata*, which plays a pivotal role in host adherence by recognizing host glycans as high-affinity receptors was found to be affected.³⁵ Another study³⁶ that aimed to identify genomic modifications occurring in *S. aureus* isolates colonizing the nares as they progressed to bacteremia in eight patients did not reveal the addition of new virulence genes. Our findings suggested that the CRA genome remained relatively stable during the transition from respiratory tract colonization to bloodstream infection, and did not undergo frequent genetic recombination or clonal selection, which was consistent with a genomic analysis of consecutive *A. baumannii* strains from a single patient.³⁷

To the best of our knowledge, this is the first study to examine the homology between colonizing and bloodstream CRA strains. However, the retrospective nature of the study limited our ability to comprehensively assess patients, as inclusion relied on physician clinical judgment. Additionally, the stress of freezing may have altered microbiological features.

In conclusion, our analysis of clinical data suggested that *Acinetobacter* spp. colonization increased the risk of subsequent antibiotic-resistant *Acinetobacter* spp. BSI, leading to elevated inflammation markers during bacteremia and higher 30-day mortality. Strict infection control measures are necessary to manage *Acinetobacter* spp. colonisation in haematological patients. Moreover, the identical genomospecies, nearly identical drug-resistance profiles, high genetic similarity based on MLST and SNP analysis, and limited within-host evolution indicated that these patients developed CRA BSI from colonizing CRA isolates in the respiratory tract. Therefore, appropriate empirical therapy can be administered for suspected CRA BSI based on the antimicrobial minimum inhibitory concentration of CRA colonising the respiratory tract.

Patient Consent Statement

We have obtained written informed consent from the patient or patient's parent/guardian.

Data Sharing Statement

The datasets generated and/or analysed during the current study are available in the GenBank repository. You can access them through the following web link: <https://www.ncbi.nlm.nih.gov/nuccore/?term=PRJNA883531>, and the accession number is PRJNA883531.

Ethics Approval Statement

The study design was approved by the Ethics Committee of the Blood Diseases Hospital, Chinese Academy of Medical Sciences. Lot number: IIT2022071-EC-1. Please refer to the attached file.

Acknowledgments

Thanks are due to Fupin Hu and Siquan Shen for bioinformatics analysis.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This work was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (grant numbers 2021-I2M-1-017, 2021-I2M-C&T-B-080), and the Tianjin Municipal Science and Technology Commission Grant (grant number 21JCZDJC01170).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Tavares LCB, Cunha MPV, De Vasconcelos FM, et al. Genomic and clinical characterization of IMP-1-producing multidrug-resistant *Acinetobacter bereziniae* isolates from bloodstream infections in a Brazilian tertiary hospital. *Microb Drug Resist*. 2020;26(11):1399–1404. doi:10.1089/mdr.2019.0210
2. Baraka A, Traglia GM, Montana S, et al. An *Acinetobacter non-baumannii* population study: antimicrobial resistance genes (ARGs). *Antibiotics*. 2020;10(1). doi:10.3390/antibiotics10010016
3. Lee HY, Chen CL, Wu SR, et al. Risk factors and outcome analysis of *Acinetobacter baumannii* complex bacteremia in critical patients. *Crit Care Med*. 2014;42(5):1081–1088. doi:10.1097/CCM.0000000000000125
4. Wisplinghoff H, Paulus T, Lugenheim M, et al. Nosocomial bloodstream infections due to *Acinetobacter baumannii*, *Acinetobacter pittii* and *Acinetobacter nosocomialis* in the United States. *J Infect*. 2012;64(3):282–290. doi:10.1016/j.jinf.2011.12.008
5. Balkhair A, Al-Muharrmi Z, Al'adawi B, et al. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*: description of a decade-long trend. *Int J Infect Dis*. 2019;85:10–15. doi:10.1016/j.ijid.2019.05.004
6. Freire MP, De Oliveira Garcia D, Garcia CP, et al. Bloodstream infection caused by extensively drug-resistant *Acinetobacter baumannii* in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. *Clin Microbiol Infect*. 2016;22(4):352–358. doi:10.1016/j.cmi.2015.12.010
7. Leao AC, Menezes PR, Oliveira MS, et al. *Acinetobacter* spp. are associated with a higher mortality in intensive care patients with bacteremia: a survival analysis. *BMC Infect Dis*. 2016;16:386. doi:10.1186/s12879-016-1695-8
8. Zilberberg MD, Nathanson BH, Sulham K, et al. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in *Acinetobacter baumannii* pneumonia and sepsis. *Crit Care*. 2016;20(1):221. doi:10.1186/s13054-016-1392-4
9. Zasowski EJ, Bassetti M, Blasi F, et al. A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial infections. *Chest*. 2020;158(3):929–938. doi:10.1016/j.chest.2020.03.087
10. Choi SH, Cho EB, Chung JW, et al. Changes in the early mortality of adult patients with carbapenem-resistant *Acinetobacter baumannii* bacteremia during 11 years at an academic medical center. *J Infect Chemother*. 2019;25(1):6–11. doi:10.1016/j.jiac.2018.09.011
11. Kim SY, Cho SI, Bang JH. Risk factors associated with bloodstream infection among patients colonized by multidrug-resistant *Acinetobacter baumannii*: a 7-year observational study in a general hospital. *Am J Infect Control*. 2020;48(5):581–583. doi:10.1016/j.ajic.2019.07.025
12. Lee JY, Kang CI, Ko JH, et al. Clinical features and risk factors for development of breakthrough gram-negative bacteremia during carbapenem therapy. *Antimicrob Agents Chemother*. 2016;60(11):6673–6678. doi:10.1128/AAC.00984-16

13. Vanegas JM, Salazar-Ospina L, Roncancio GE, et al. Staphylococcus aureus colonization increases the risk of bacteremia in hemodialysis patients: a molecular epidemiology approach with time-dependent analysis. *Am J Infect Control*. 2021;49(2):215–223. doi:10.1016/j.ajic.2020.05.031
14. Silago V, Kovacs D, Msanga DR, et al. Bacteremia in critical care units at Bugando Medical Centre, Mwanza, Tanzania: the role of colonization and contaminated cots and mothers' hands in cross-transmission of multidrug resistant Gram-negative bacteria. *Antimicrob Resist Infect Control*. 2020;9(1):58. doi:10.1186/s13756-020-00721-w
15. Jung JY, Park MS, Kim SE, et al. Risk factors for multi-drug resistant *Acinetobacter baumannii* bacteremia in patients with colonization in the intensive care unit. *BMC Infect Dis*. 2010;10:228. doi:10.1186/1471-2334-10-228
16. Satlin MJ, Chavda KD, Baker TM, et al. Colonization with levofloxacin-resistant extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk of bacteremia in hematopoietic stem cell transplant recipients. *Clin Infect Dis*. 2018;67(11):1720–1728. doi:10.1093/cid/ciy363
17. Chiang DH, Wang CC, Kuo HY, et al. Risk factors for mortality in patients with *Acinetobacter baumannii* bloodstream infection with genotypic species identification. *J Microbiol Immunol Infect*. 2008;41(5):397–402.
18. Diekema DJ, Beekmann SE, Chapin KC, et al. Epidemiology and outcome of nosocomial and community-onset bloodstream infection. *J Clin Microbiol*. 2003;41(8):3655–3660. doi:10.1128/JCM.41.8.3655-3660.2003
19. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
20. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Crit Care Med*. 2021;49(11):e1063–e1143. doi:10.1097/CCM.0000000000005337
21. Pierce VM, Bhowmick T, Simner PJ. Guiding antimicrobial stewardship through thoughtful antimicrobial susceptibility testing and reporting strategies: an updated approach in 2023. *J Clin Microbiol*. 2023;61(11):e0007422. doi:10.1128/jcm.00074-22
22. Rinke C, Chuvochina M, Mussig AJ, et al. A standardized archaeal taxonomy for the genome taxonomy database. *Nat Microbiol*. 2021;6(7):946–959. doi:10.1038/s41564-021-00918-8
23. Tan KK, Tan YC, Chang LY, et al. Full genome SNP-based phylogenetic analysis reveals the origin and global spread of *Brucella melitensis*. *BMC Genomics*. 2015;16(1):93. doi:10.1186/s12864-015-1294-x
24. Tomaschek F, Higgins PG, Stefanik D, et al. Head-to-head comparison of two multi-locus sequence typing (MLST) schemes for characterization of *Acinetobacter baumannii* outbreak and sporadic isolates. *PLoS One*. 2016;11(4):e0153014. doi:10.1371/journal.pone.0153014
25. Khurshid M, Rasool MH, Ashfaq UA, et al. Dissemination of blaOXA-23-harboring carbapenem-resistant *Acinetobacter baumannii* clones in Pakistan. *J Glob Antimicrob Resist*. 2020;21:357–362. doi:10.1016/j.jgar.2020.01.001
26. Wang X, Zhang L, Sun A, et al. *Acinetobacter baumannii* bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the infection working party of Jiangsu society of hematology. *Eur J Clin Microbiol Infect Dis*. 2017;36(7):1073–1081. doi:10.1007/s10096-016-2895-2
27. Li J, Feng X, Wang J, et al. *Acinetobacter* spp. bloodstream infection in hematological patients: a 10-year single-center study. *BMC Infect Dis*. 2023;23(1):796. doi:10.1186/s12879-023-08789-6
28. Sheek E, Romanov A, Shapovalova V, et al. *Acinetobacter* non-*baumannii* species: occurrence in infections in hospitalized patients, identification, and antibiotic resistance. *Antibiotics*. 2023;12(8):1.
29. Jang TN, Lee SH, Huang CH, et al. Risk factors and impact of nosocomial *Acinetobacter baumannii* bloodstream infections in the adult intensive care unit: a case-control study. *J Hosp Infect*. 2009;73(2):143–150. doi:10.1016/j.jhin.2009.06.007
30. Chen Q, Zheng Z, Shi Q, et al. Multidrug-resistant *Acinetobacter baumannii* may cause patients to develop polymicrobial bloodstream infection. *Can J Infect Dis Med Microbiol*. 2022;2022:8368578. doi:10.1155/2022/8368578
31. Playford EG, Craig JC, Iredell JR. Carbapenem-resistant *Acinetobacter baumannii* in intensive care unit patients: risk factors for acquisition, infection and their consequences. *J Hosp Infect*. 2007;65(3):204–211. doi:10.1016/j.jhin.2006.11.010
32. Arvaniti K, Lathyris D, Ruimy R, et al. The importance of colonization pressure in multiresistant *Acinetobacter baumannii* acquisition in a Greek intensive care unit. *Crit Care*. 2012;16(3):R102. doi:10.1186/cc11383
33. E TB, Paterson DL, Kamolvit W, et al. Species identification within *Acinetobacter calcoaceticus-baumannii* complex using MALDI-TOF MS. *J Microbiol Methods*. 2015;118:128–132. doi:10.1016/j.mimet.2015.09.006
34. Mao P, Deng X, Yan L, et al. Whole-genome sequencing elucidates the epidemiology of multidrug-resistant *Acinetobacter baumannii* in an intensive care unit. *Front Microbiol*. 2021;12:715568. doi:10.3389/fmicb.2021.715568
35. Tram G, Poole J, Adams FG, et al. The *Acinetobacter baumannii* autotransporter adhesin recognizes host glycans as high-affinity receptors. *ACS Infect Dis*. 2021;7(8):2352–2361. doi:10.1021/acinfeddis.1c00021
36. Benoit JB, Frank DN, Bessesen MT. Genomic evolution of *Staphylococcus aureus* isolates colonizing the nares and progressing to bacteremia. *PLoS One*. 2018;13(5):e0195860. doi:10.1371/journal.pone.0195860
37. Kim SJ, Kim YJ, Ko KS. Genomic analysis of consecutive *Acinetobacter baumannii* strains from a single patient. *Front Microbiol*. 2018;9:2840. doi:10.3389/fmicb.2018.02840

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>